SARS-CoV-2 İlişkili Yoğun Bakım Hastalarında Septik Şoka Neden Olan Sekonder Enfeksiyonların Prokalsitonin, CRP, Lökosit ve COVİD-19 Aşılanma İle İlişkisi

Yıl 2025, Cilt: 58 Sayı: 3, 95 - 100, 24.02.2026

Yasemin Bozkurt Turan

https://izlik.org/JA62MN59AK

Öz

AMAÇ
Şiddetli ve kritik COVID-19 hastalarda sekonder enfeksiyonların daha yüksek bir mortalite oranına yol açtığı görülmüştür. Bununla birlikte, aşıların geliştirilmesiyle COVID-19 ilişkili mortalite oranı azalmıştır. Bu çalışmada COVID-19 tanılı yoğun bakım hastalarında, sekonder enfeksiyona bağlı septik şok gelişimi ile COVID-19 aşılama arasında nasıl bir ilişki olduğunun araştırılması ve sekonder enfeksiyon etkenleri ve dağılım oranlarının değerlendirilmesi amaçlandı. Aynı zamanda bu hasta grubunda uygulanan ampirik antimikrobiyal tedavi öncesi ve sonrası CRP, prokalsitonin ve lökosit değerlerinin klinik kötüleşme ile korelasyonu değerlendirildi.
GEREÇ VE YÖNTEM
Çalışma COVID-19 enfeksiyon tanısı alan (nazofarengeal sürüntü örneği RT-PCR ile doğrulanan), yoğun bakım yatışı sırasında sekonder enfeksiyona bağlı septik şok gelişen, 18 yaş üstü hastalarda retrospektif, kesitsel ve tek merkezli olarak yapıldı.
BULGULAR
Hastaların medyan yaşı 69 (23-95) olup %54,6’sının erkek olduğu görülmüştür. 28 günlük mortalite oranı %80,4 (n=225) olarak bulunmuştur. Hastaların yoğun bakım medyan yatış süresi 18 (3-106) gün olarak hesaplandı. Hastaların %77,1'inde (n=216) ek hastalık mevcuttu. Hastaların %76,1'inde (n=213) sekonder enfeksiyon gelişmişti. Erkekler arasında mortalite oranı anlamlı derecede yüksek bulundu (p=0,006). Aşılanmamış hasta grubunda mortalite oranı (n=143, %85,1) aşılanmış gruba göre anlamlı derecede yüksek saptanmıştır (p=0,014). Ölen hasta grubunda ampirik antimikrobiyal tedavi öncesi ve sonrası ortalama prokalsitonin ve lökosit değerleri, sağ kalanlara göre anlamlı derecede yüksekti (p<0,05). Aşılanmamış hasta grubunda toplam sekonder enfeksiyon görülme oranı %83,3 (n=140) olup, aşı yapılan hasta grubuna göre anlamlı derecede yüksekti (p<0,01).
SONUÇ
COVID-19 yoğun bakım ünitesine kabul edilen aşılanmamış hasta grubunda sekonder enfeksiyon oranı önemli ölçüde yüksektir. Bu durum mortalite açısından bir risk teşkil etmektedir. Prokalsitonin ve lökosit değerleri ampirik antimikrobiyal tedavi öncesi ve sonrası mortaliteyi göstermesine rağmen CRP gösterememiştir.
Anahtar kelimeler
SARS-CoV-2, sekonder enfeksiyon, COVID-19 aşı, prokalsitonin, lökosit

Anahtar Kelimeler

SARS-CoV-2 , sekonder enfeksiyon , COVID-19 aşı , prokalsitonin , lökosit

The Relationship between Secondary Infections Causing Septic Shock and Procalcitonin, CRP, and Leukocyte Values and COVID-19 Vaccination in SARS-CoV-2-Related Intensive Care Patients

https://izlik.org/JA62MN59AK

Öz

AIM
Secondary infections in patients with severe and critical COVID-19 have been seen to entail a higher mortality rate. However, COVID-19-related mortality declined with the development of vaccines. The purpose of this study was to examine the relationship between septic shock development associated with secondary infection and COVID-19 vaccination in patients with COVID-19 and to evaluate the agents of secondary infection and their distribution patterns. This research also evaluated the correlation between pre- and post-empiric antimicrobial therapy CRP, leukocyte, and procalcitonin values and clinical worsening.
MATERIAL AND METHOD
This retrospective, cross-sectional, single-center study was conducted with patients aged over 18, diagnosed with COVID-19 (confirmed by nasopharyngeal swab RT-PCR), and developing septic shock in association with secondary infection during their ICU stays.
RESULTS
The patients’ median age was 69 years (23-95), and 54.60% were men. The 28-day mortality rate was 80.4% (n=225), and the median length of stay in the ICU was 18 days (3-106). Additional disease was present in 77.1% (n=216) of patients. Secondary infection developed in 76.10% (n=213) of the patients. The exitus rate was significantly higher among men (p=0.006). The exitus rate among the unvaccinated individuals, 85.1% (n=143), was significantly higher than in the vaccinated group (p=0.014). Mean pre- and post-empiric antimicrobial therapy procalcitonin and leukocyte values were significantly higher in the exitus cases than in the survivors (p<0.05). The total incidence of secondary infections, 83.3% (n=140), was significantly higher in the unvaccinated patient group than in the vaccinated patients (p<0.01).
CONCLUSION
The secondary infection rate were significantly high in the unvaccinated patient group admitted to the COVID-19 ICU. This represents a risk in terms of mortality. Although procalcitonin and leukocyte values indicated pre- and post-empiric antimicrobial therapy mortality, CRP was unable to do so.
Key words
SARS-CoV-2, secondary infection, COVID‐19 vaccine, procalcitonin, leukocyte

Anahtar Kelimeler

SARS-CoV-2 , secondary infection , COVID‐19 vaccine , procalcitonin , leukocyte

Kaynakça

• 1. Chen X, Liao B, Cheng L, Peng X, Xu X, Li Y et al. The microbial coinfection in COVID-19. Appl Microbiol Biotechnol. 2020 Sep;104(18):7777-7785. doi: 10.1007/s00253-020-10814-6.
• 2. Zhang H, Zhang Y, Wu J, Li Y, Zhou X, Li X, et al. Risks and features of secondary infections in severe and critical ill COVID-19 patients. Emerg Microbes Infect. 2020 Dec;9(1):1958-1964. doi: 10.1080/22221751.2020.1812437.
• 3. Hodges G, Pallisgaard J, Schjerning Olsen AM, McGettigan P, Andersen M, Krogager M. Association between biomarkers and COVID-19 severity and mortality: a nationwide Danish cohort study. BMJ Open. 2020;10. doi: 10.1136/bmjopen-2020-041295.
• 4. Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med. 2021 Jun;26(3):107-108. doi: 10.1136/bmjebm-2020-111536.
• 5. Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. Int J Antimicrob Agents. 2020;56. doi: 10.1016/j. ijantimicag.2020.106051.
• 6. Zhou Z, Zhu Y, Chu M. Role of COVID-19 Vaccines in SARSCoV-2 Variants. Front Immunol. 2022 May 20;13:898192. doi: 10.3389/fimmu.2022.898192.
• 7. Zawbaa HM, Osama H, El-Gendy A, Saeed H, Harb HS, Madney YM, et al. Effect of mutation and vaccination on spread, severity, and mortality of COVID-19 disease. J Med Virol. 2022 Jan;94(1):197-204. doi: 10.1002/jmv.27293.
• 8. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am J Respir Crit Care Med. 2020 Jun 1;201(11):1380-1388.
• 9. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020 Dec;26(12):1622-1629. doi: 10.1164/ rccm.202002-0445OC.
• 10. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054– 1062. doi: 10.1016/S0140-6736(20)30638-3.
• 11. Li J, Wang J, Yang Y, Cai P, Cao J, Cai X, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrob Resist Infect Control. 2020 Sep 22;9(1):153. doi: 10.1186/s13756-020-00819-1.
• 12. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.
• 13. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495–1499. doi: 10.1016/j.ijsu.2014.07.013.
• 14. Zhong H, Wang Y, Shi Z, Zhang L, Ren H, He W, et al. Characterization of respiratory microbial dysbiosis in hospitalized COVID-19 patients. Cell Discov. 2021;7(1):23. doi: 10.1038/s41421-021- 00257-2.
• 15. Chong WH, Saha BK, Ramani A, Chopra A. State-of-the-art review of secondary pulmonary infections in patients with COVID-19 pneumonia. Infection. 2021 Aug;49(4):591-605. doi: 10.1007/ s15010-021-01602-z.
• 16. Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol. 2018 Feb;16(2):91-102. doi: 10.1038/nrmicro.2017.148.
• 17. Fazel P, Sedighian H, Behzadi E, Kachuei R, Imani Fooladi AA. Interaction Between SARS-CoV-2 and Pathogenic Bacteria. Curr Microbiol. 2023 May 24;80(7):223. doi: 10.1007/s00284-023- 03315-y.
• 18. Manna S, Baindara P, Mandal SM. Molecular pathogenesis of secondary bacterial infection associated to viral infections including SARS-CoV-2. J Infect Public Health. 2020 Oct;13(10):1397- 1404. doi: 10.1016/j.jiph.2020.07.003.
• 19. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140- 6736(20)30211-7.
• 20. Erdal B, Keskin B, Altıntaş N, Kiraz N. COVİD-19 Hastalarında Sekonder Enfeksiyonlar ve Literatürün Gözden Geçirilmesi: Üniversite Hastanesinde Yapılan Retrospektif Bir Çalışma. ANKEM Derg. 2022;36(2):64-73. doi: 10.54962/ankemderg.1163275.
• 21. Suleiman AS, Islam MA, Akter MS, Amin MR, Werkneh AA, Bhattacharya P. A meta-meta-analysis of co-infection, secondary infections, and antimicrobial resistance in COVID-19 patients. J Infect Public Health. 2023 Oct;16(10):1562-1590. doi: 10.1016/j. jiph.2023.07.005.
• 22. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x.
• 23. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/ S2213-2600(20)30079-5.
• 24. Tasdelen Fisgin N, Aliyazicioglu Y, Tanyel E, Coban AY, Ulger F, Zivalioglu M, et al. The value of neopterin and procalcitonin in patients with sepsis. Southern Medical Journal 2010;103(3):2169. doi: 10.1097/SMJ.0b013e3181cf11a1.
• 25. Tsalik EL, Jaggers LB, Glickman SW, Langley RJ, Velkinburgh JC, Park LP, et al. Discriminative value of inflammatory biomarkers for suspected sepsis. Journal of Emergency Medicine 2012;43(1):97106. doi: 10.1016/j.jemermed.2011.05.072.
• 26. Naoum FA, Ruiz ALZ, Martin FHO, Brito THG, Hassem V, Oliveira MGL. Diagnostic and prognostic utility of WBC counts and cell population data in patients with COVID-19. Int J Lab Hematol. 2021 Jul;43 Suppl 1(Suppl 1):124-128. doi: 10.1111/ijlh.13395